Hidradenitis suppurativa (HS)
HUMIRA is the first and only originator biologic* indicated in the treatment of HS†
HUMIRA is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics).
* Also known as a reference biologic.
† Comparative clinical significance has not been established.
Recommended dosing
FOR ADULTS – WEEKLY DOSING STARTING AT WEEK 4 AND THEREAFTER1
Recommended dosing for adult patients with HS*
† Administered as four injections in one day, or two injections per day for two consecutive days.
• Antibiotics may be continued during treatment with HUMIRA, if necessary.
• In patients without any benefit after 12 weeks of treatment, continued therapy should be reconsidered.
FOR ADOLESCENTS – EVERY-OTHER-WEEK DOSING STARTING AT WEEK 11
Recommended dosing for adolescent patients (12 to 17 years of age weighing ≥30 kg) with HS*
• In adolescent patients with inadequate response to HUMIRA 40 mg every other week, an increase in dosing frequency to 40 mg weekly may be considered.
• Antibiotics may be continued during treatment with HUMIRA if necessary.
• Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement within this time period.
* Patients may self-inject HUMIRA if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.
Safety information:
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma, serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic disease-modifying antirheumatic drugs (DMARDs) or other tumour necrosis factor (TNF) antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
Reference:
1. HUMIRA Product Monograph. AbbVie Corporation.